Biography

Michael is a T-cell Immunologist with over 20 years of experience in the field, including 16 years in the cancer immunotherapy industry. Throughout his career, he has contributed to the development of cancer immunotherapeutics, progressing from R&D stages to Phase II clinical trials, with a focus on overseeing patient immunomonitoring strategies. For the past nine years, Michael has served as Vice President of Immuno-Oncology at Evotec, leading the Immuno-Oncology therapeutic area. Since 2019, he has been a member of the Cell Therapy core team, supporting the immunological characterization of iPSC-based immune cell therapies. In 2021, he was appointed Review Editor for T-cell Biology at Frontiers in Immunology. Michael's scientific career has been driven by a deep interest in understanding the biological mechanisms of immune response modulation and applying this knowledge to develop innovative cancer therapeutics. He has also contributed to numerous projects involving diverse therapeutic modalities, guiding them from early discovery to IND submissions and clinical trials. His work includes designing and overseeing biomarker strategies to monitor immune responses in patients, validating preclinical data, and supporting the clinical development of therapeutic candidate.